Halovate Lotion contains Halobetasol 0.05% w/v, a potent topical corticosteroid indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Halobetasol exerts anti-inflammatory, antipruritic, and vasoconstrictive effects by modulating the release of inflammatory mediators and suppressing the immune response in affected skin areas. This formulation is primarily used in conditions such as psoriasis, eczema, lichen planus, and other corticosteroid-responsive dermatoses where rapid symptomatic relief is desired. Halovate Lotion should be applied sparingly to the affected area once or twice daily, as directed by a healthcare professional, and treatment duration should be limited to avoid potential adverse effects associated with prolonged corticosteroid use, including skin atrophy, telangiectasia, and hypothalamic-pituitary-adrenal axis suppression. It is contraindicated in patients with hypersensitivity to halobetasol or any components of the formulation, as well as in viral, fungal, or bacterial skin infections unless appropriate antimicrobial therapy is concurrently administered. Caution is advised when using Halovate Lotion on large surface areas, under occlusion, or in pediatric populations. Patients should be advised to avoid contact with eyes and mucous membranes and to discontinue use if irritation or sensitization occurs.